Categorization of patients with systemic lupus erythematosus using disease activity, patient-reported outcomes, and transcriptomic signatures.
Robin ArcaniElisabeth JouveLaurent ChicheNoémie Jourde-ChichePublished in: Clinical rheumatology (2023)
Patients with SLE can be categorized into four clinical groups using the SLEDAI score and our SF-36-derived type 2 score. This categorization is non-redundant with immunological or transcriptomic profiles and could prove useful to stratify patients in clinical trials. Key Points • A score derived from selected items of the SF-36 can be used to identify SLE patients with type 2 symptoms according to the Duke University categorization. • Using the SLEDAI and this type 2 score, SLE patients can be categorized into four clinical groups. • This categorization is not related to immunological activity or blood transcriptome profiles (and not to the interferon signature in particular). • This categorization could be useful in the daily care of patients as well as in clinical trials, for upstream patient stratification or for the interpretation of results.
Keyphrases
- disease activity
- patient reported outcomes
- end stage renal disease
- systemic lupus erythematosus
- clinical trial
- ejection fraction
- chronic kidney disease
- newly diagnosed
- rheumatoid arthritis
- peritoneal dialysis
- prognostic factors
- physical activity
- single cell
- dendritic cells
- open label
- pain management
- case report
- depressive symptoms
- juvenile idiopathic arthritis
- chronic pain